Ferring and GenerationS summed up the results of an open call for innovative projects in reproductive medicine and fertility
Ferring Pharmaceuticals, а Swiss Biopharmaceutical Company, summed up the results of an open call for innovative projects powered by GenerationS. The winning team selected by the expert jury will receive a prize of 10,000 euros for project development.
The open call was announced in April 2019. In total, more than 70 startups from Russia, Ukraine, Estonia, Kazakhstan, Armenia, Uzbekistan and India were assessed.
Eight teams were shortlisted, offering the most promising solutions in the field of new peptide technologies, oocyte maturation media, 3d bioprinting technologies, decision-support systems for assisted reproductive technology (ART) centers, and others. Some of the finalists will have an opportunity to continue cooperation with the global Ferring team for further projects development and implementation.
Recognized specialists in the field of reproductive medicine, prominent representatives of science and business took part in the evaluation of projects. Their extensive professional experience allowed to assess both Russian and foreign startups.
The jury selected one startup team, which will receive 10,000 euros for the development of its technology. The project offers unique media for ovarian tissue vitrification to preserve fertility and conduct menopausal hormone therapy in patients of different age groups. With the support of leading Ferring experts, the startup will be able to bring its solution to a commercial product.
Kirill Litovchenko, General Manager of Ferring Pharmaceuticals Russia and Eurasia:
«Our joint efforts with GenerationS managed to attract a number of promising projects in the field of reproductive medicine and fertility. Based on the results of the scouting and evaluation, we are pleased to support the project that develops new methods that will expand the boundaries of the reproductive period and enable women to become mothers of healthy children even after cancer. We will also continue to cooperate with other projects to help them improve their technology and introduce new reproductive health solutions to the world».
Ekaterina Petrova, director of GenerationS corporate accelerator:
«We are pleased to launch a joint project with Ferring, which gave us new interesting experience, allowing us to dive deeper into the pharmaceutical industry and understand what technologies can be in demand on the market. The significance of the joint initiative was also in social importance - reproductive medicine, for which we managed to find promosing projects. We hope that the proposed technologies will contribute not only to the development of the company, but also to the pharmaceutical industry worldwide».
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a biopharmaceutical company engaged in search, development and implementation of the innovation products in reproductive healthcare, oncology, urology, gastroenterology, endocrinology and orthopaedics. Company research activity and products serve a single purpose - to create specialized medication able to fight various diseases and pathologies, using the human organism’s resources and functional potential. Marketing, medical services, retail and wholesale subdivisions of Ferring work in almost 60 countries, management is done from the headquarters in Saint-Prex, Switzerland.